Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker NUVB · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued V… NCT07703436 · Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma Safusidenib | NUVB Nuvation Bio Inc. | Phase 2 | Recruiting | 40 | Sep 2030 | Registry ↗ |
| Oct 19, 2026 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) NCT05303519 · Glioma, Astrocytoma, Grade IV safusidenib, Placebo | NUVB Nuvation Bio Inc. | Phase 3 | Recruiting | 365 | Dec 1, 2028 | Registry ↗ |
| Aug 3, 2026 | Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib NCT07742384 · Healthy Adult Participants Taletrectinib, Taletrectinib, Famotidine | NUVB Nuvation Bio Inc. | Phase 1 | Not yet recruiting | 56 | Feb 2, 2027 | Registry ↗ |
| Jul 17, 2026 | Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma NCT07712757 · Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an I… Safusidenib, Placebo | NUVB Nuvation Bio Inc. | Phase 3 | Not yet recruiting | 140 | May 2029 | Registry ↗ |
| May 19, 2026 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) NCT07154706 · Non-small Cell Lung Cancer (NSCLC) Taletrectinib, Placebo | NUVB Nuvation Bio Inc. | Phase 3 | Recruiting | 180 | Aug 30, 2030 | Registry ↗ |
| Apr 13, 2026 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced o… NCT06564324 · Non Small Cell Lung Cancer Taletrectinib, Crizotinib | NUVB Nuvation Bio Inc. | Phase 3 | Recruiting | 194 | Jan 2029 | Registry ↗ |
| Feb 6, 2026 | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene NCT04395677 · Non Small Cell Lung Cancer AB-106 | NUVB Nuvation Bio Inc. | Phase 2 | Active, not recruiting | 173 | Jun 7, 2024 | Registry ↗ |
| Jan 21, 2026 | Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion NCT04617054 · Solid Tumor AB-106 | NUVB Nuvation Bio Inc. | Phase 2 | Terminated | 14 | Dec 6, 2024 | Registry ↗ |
| Jan 14, 2026 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors NCT06334432 · Advanced Solid Tumor, HER2-negative Breast Cancer NUV-1511 | NUVB Nuvation Bio Inc. | Phase 1/2 | Active, not recruiting | 466 | Mar 2027 | Registry ↗ |
| Jan 7, 2026 | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC NCT04919811 · Non Small Cell Lung Cancer Taletrectinib | NUVB Nuvation Bio Inc. | Phase 2 | Active, not recruiting | 217 | Jun 11, 2025 | Registry ↗ |
| Dec 24, 2025 | Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC NCT06841874 · Lung Neoplasms, Respiratory Tract Neoplasms Taletrectinib | NUVB Nuvation Bio Inc. | — | No longer available | — | — | Registry ↗ |
| Nov 6, 2025 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Adva… NCT05252390 · Advanced Solid Tumor, Ovarian Cancer NUV-868, Olaparib | NUVB Nuvation Bio Inc. | Phase 1 | Terminated | 82 | Jul 15, 2024 | Registry ↗ |
| Jun 24, 2025 | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b NCT02279433 · Solid Tumors DS6051b | NUVB Nuvation Bio Inc. | Phase 1 | Completed | 46 | Mar 2019 | Registry ↗ |
| Nov 21, 2024 | Study the Effect of Omeprazole on AB-106 Pharmacokinetics NCT05609929 · Pharmacokinetic Study Multiple administration of omeprazole Single administration… | NUVB Nuvation Bio Inc. | Phase 1 | Completed | 24 | Jan 20, 2023 | Registry ↗ |
| Nov 21, 2024 | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin NCT05357911 · Solid Tumor AB-106, digoxin | NUVB Nuvation Bio Inc. | Phase 1 | Completed | 16 | Aug 20, 2021 | Registry ↗ |
| Nov 21, 2024 | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin… NCT05357820 · Solid Tumor AB-106, Itraconazole, AB-106, Rifampicin | NUVB Nuvation Bio Inc. | Phase 1 | Completed | 56 | Dec 3, 2021 | Registry ↗ |
| Jul 14, 2023 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NCT04541225 · Glioma, Glioma, Malignant NUV-422 | NUVB Nuvation Bio Inc. | Phase 1 | Terminated | 74 | Aug 31, 2022 | Registry ↗ |
| Jul 11, 2023 | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC NCT05191004 · Advanced Breast Cancer, Metastatic Breast Cancer NUV-422, Fulvestrant | NUVB Nuvation Bio Inc. | Phase 1/2 | Withdrawn | 0 | Jun 2025 | Registry ↗ |
| Aug 5, 2022 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC NCT05191017 · Prostate Cancer, Prostatic Cancer NUV-422, Enzalutamide | NUVB Nuvation Bio Inc. | Phase 1/2 | Withdrawn | 0 | Jan 2025 | Registry ↗ |
19 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:58 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances